Welcome to BioLegend’s one-of-a-kind advanced search. Search by any one of the single fields below or narrow down your searches by using multiple parameters. Looking for an anti-mouse NK cell antibody for IHC? Or looking for a FITC-conjugated antibody against a human marker for dendritic cells to use for flow cytometry? Only BioLegend’s advanced search can provide you with the best answers. If you have further questions, please contact our technical service team at 858-768-5801.
Use this document lookup tool to find Current Product Datasheets, Certificates of Analysis, or MSDS for any antibody products you have purchased from BioLegend.
Use the search box below to perform a site search of BioLegend.com powered by Google™.
The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.
Concentration:
0.5 mg/ml
Storage & Handling:
The antibody solution should be stored undiluted at 4°C. Do not freeze.
Each lot of this antibody is quality control tested by ELISA assay. For ELISA or ELISPOT detection, the antibody should be titrated between 0.25-1.0 µg/ml to determine optimal conditions. To obtain a linear standard curve, serial dilutions of IL-10 recombinant protein ranging from 2000 to 15 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.
COA:
Application Notes:
ELISA or ELISPOT Detection1,9,11: The biotinylated JES5-16E3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified JES5-2A5 antibody (Cat. No. 504902/504904) as the capture antibody.
Neutralization: The JES5-16E3 antibody can neutralize the bioactivity of natural or recombinant IL-10.
Application References:
1. Simkin G, et al. 2000. J. Immunol. 164:2457. 2. Kitagaki K, et al. 2002. Clin. Diagn. Lab Immunol. 9:1260. 3. Khanna A, et al. 2000. J. Immunol. 164:1346. 4. Sander B, et al. 1993. J. Immunol. Methods 166:201. 5. Litton M, et al. 1994. J. Immunol. Methods 175:47. 6. Andersson U, et al. 1999. Detection and qunatification of gene expression. New York:Springer-Verlag. 7. Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons New York. Unit 6.28. 8. Wang W, et al. 2004. FASEB J. 18:1043. 9. Brummel R and Lenert P. 2005. J. Immunol. 174:2429. 10. Lawson BR, et al. 2007. J. Immunol. 178:5366. 11. Xu G, et al. 2007. J. Immunol. 179:5358. PubMed 12. Brummel R, et al. 2005. J. Immunol.174:2429. PubMed 13. Kang YJ, et al. 2007. Stem Cells 25:1814. PubMed
IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRFI. IL-10 inhibits IFN-γ, TNF-β, and IL-2 production by Th1 clones; inhibits macrophage-mediated IL-1, IL-6, and TNF-α synthesis; suppresses the delayed type hypersensitivity response; stimulates Th2 cell response (which results in elevated antibody production); and promotes mast cell proliferation in combination with IL-4.
Other Names:
Interleukin-10, Cytokine synthesis inhibitory factor (CSIF), B cell derived T cell growth factor (B-TCGF), T cell growth inhibitory factor (TGIF)
Structure:
Acid-labile cytokine, dimer, 17-21 kD (Mammalian)
Regulation:
Downregulated by IL-4, IL-10
Cellular Sources:
Activated CD8+ T cells, Th0, Th2 subset of CD4+ T cells, Ly-1+ B cells, monocytes, macrophages, keratinocytes
Cellular Targets:
T cells, B cells, mast cells, macrophages
Receptors:
IL-10R (CDw210)
Antigen References:
1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. de Waal-Malefy R, et al. 1992. Curr. Opin. Immunol. 4:314. 3. Howard M, et al. 1992. Immunol. Today 13:198. 4. Quesniaux V. 1992. Res. Immunol. 143:385. 5. Norton SK, et al. 2008. J. Immunol. 180:2848.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
This data display is provided for general comparisons between formats. Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors. If you need assistance with selecting the best format contact our expert technical support team.
APC anti-mouse IL-10
PMA/ionomycin-stimulated Th2-polarized Balb/c mouse splenocytes were intracellular stained with JES5-16E3 APC and CD3 (17A2) PE
Biotin anti-mouse IL-10
FITC anti-mouse IL-10
PMA-restimulated Th2-polarized C57BL/6 mouse splenocytes surface stained with CD3 APC, then intracellularly stained with JES5-16E3 FITC (top) or rat IgG2b, κ FITC isotype control (bottom).
PE anti-mouse IL-10
PMA/Ionomycin-stimulated Th2-polarized Balb/c mouse splenocytes were surface stained with CD4 PE/Cy5 and then intracellularly stained with JES5-16E3 PE.
Purified anti-mouse IL-10
Alexa Fluor® 647 anti-mouse IL-10
PMA/ionomycin-stimulated Th2-polarized Balb/c mouse splenocytes were intracellular stained with JES5-16E3 Alexa Fluor® 647 and CD3 (17A2) PE
PE/Cy7 anti-mouse IL-10
PMA+ionomycin-stimulated Th2-polarized C57BL/6 mouse splenocytes (in the presence of monensin) were stained with CD3 FITC, fixed, permeabilized, and then stained with IL-10 (clone JES5-16E3) PE/Cy7 (top) or rat IgG2b PE/Cy7 isotype control (bottom).
Brilliant Violet 421™ anti-mouse IL-10
PMA+ionomycin-stimulated Th2-polarized C57BL/6 mouse splenocytes (in the presence of monensin) were stained with CD3 FITC, fixed, permeabilized, and then stained with IL-10 (clone JES5-16E3) Brilliant Violet 421™ (top) or rat IgG2b Brilliant Violet 421™ isotype control (bottom).
Pacific Blue™ anti-mouse IL-10
Th2 polarized C57BL/6 splenocytes stained with JES5-16E3 Pacific Blue™ and CD3 (17A2) PE
Th2 polarized C57BL/6 splenocytes stained with rat IgG2b isotype Pacific Blue™ and mouse CD3 antibody (17A2) PE
